Agent B

Christina undergoes general anesthesia with the second experimental agent...

The subject did not appear to have suffered any lasting physical or emotional trauma from Agent A and had slept well overnight. She was fully fit and ready for the trial of Agent B

The subject described the agent as "not so pleasant", with a strong odor of onions.

It was noticeable that it was some considerable time before the agent had any effect at all....

Finally, a full minute after induction had commenced, the subject entered stage 1 (analgesia phase)

The analgesia phase was also noticeably prolonged. The option of increasing the vapor concentration was considered, but it was decided that would reduce the quality of comparison between the different agents.

Finally, after a two full minutes in stage 1, the subject's eyelids began to flicker and there was a mild groaning, indicating the onset of stage 2 (delirium phase)

The subject finally lost consciousness three minutes into the induction

With surgical anesthesia established, anesthesia was allowed to deepen to the point where all reflexes ceased...

The subject was in surgical anesthesia for a full ten minutes before reaching the depth where her airway needed supporting. The anesthetic was turned off at this point.

Pure oxygen was then fed thru the mask to revive the subject...

The subject required ten minutes of pure oxygen before breathing comfortably on her own...

After a further hour, the subject still showed no signs of waking...

After two hours in recovery, the subject was still deeply unconscious, with breathing and pulse at the minimum acceptable level. Concerned she may go into respiratory and/or cardiac arrest, her gown was removed ready for immediate resus if needed...

In the event, the subject continued to be stable, but remained deeply unconscious...

Finally, after three hours and forty minutes in recovery, the subject began to waken...

Agent B was clearly not suitable for induction, slow to act and be absorbed, and then very slow to be eliminated from the tissues, resulting in a prolonged anesthesia and recovery.

However the agent shows excellent potential for prolonged long-term anesthesia, where only a low dose is needed to maintain deep general anesthesia, due to slow tissue elimination. An ideal market would be organisations requiring prisoners and hostages to kept sedated for prolonged periods, such as for long haul journeys, and patients needing to be in a prolonged coma to promote recovery.